Annexon Adds 24‑Month Backup Endpoint to Phase 3 ARCHER II, Raising Questions on Month 15 Threshold

What happened

Annexon announced the addition of a Month 24 dual primary endpoint to its Phase 3 ARCHER II trial of vonaprument for geographic atrophy, alongside an open-label extension study. The change means the trial can succeed if either the Month 15 or Month 24 endpoint is met, providing a second chance at regulatory success. While management presents the move as expanding the program, late‑stage endpoint modifications often signal concern that the original endpoint may be difficult to achieve, increasing uncertainty around the upcoming H2 2026 readout. The ARCHER II trial previously completed enrollment of 659 patients in mid‑2025, with the primary endpoint initially focused exclusively on preventing ≥15-letter BCVA loss at Month 15. Investors now face a wider range of possible outcomes and should monitor whether the dual-endpoint strategy complicates statistical interpretation or merely offers insurance.

Implication

Adding a 24‑month endpoint late in development can be interpreted as a hedge against a weak Month 15 signal, suggesting internal data or power concerns. If the trial succeeds only at Month 24, it would delay potential approval and give competitors more time to advance, weakening commercial positioning. The open‑label extension is standard but does not offset the increased uncertainty around the primary analysis. With the company’s cash runway extending only into early 2027, any setback in ARCHER II would force greater reliance on the GBS asset and could accelerate dilution. Investors should therefore treat the upcoming ARCHER II readout as a higher‑risk binary event, with a wider cone of possible outcomes than previously assumed.

Thesis delta

The ARCHER II design change introduces new execution risk to the GA catalyst, making a positive outcome less predictable and potentially less timely. While the GBS program remains the primary value driver, the altered trial design reduces our conviction that ARCHER II will deliver a clean, near‑term win. We maintain our BUY rating but increase the weight of monitoring on GA endpoint credibility.